DelveInsight’s “Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Herpes Simplex market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Herpes Simplex Market Forecast
Some of the key facts of the Herpes Simplex Market Report:
The Herpes Simplex market size was valued ~USD 3,159 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial for its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, failed to achieve its primary efficacy endpoint. This conclusion was drawn from an analysis of the primary objective data from the Phase II segment of the trial. Designed to offer a new therapeutic option for HSV, GSK3943104 will not be advanced to Phase III studies following the trial results.
As per DelveInsight’s analysis, the United States held the largest market share for Herpes Simplex in the 7MM, with a market size of USD 1,590 million in 2023.
In 2023, Germany led the EU4 with the largest market size for Herpes Simplex at USD 320 million, followed by the UK at USD 282 million, while Spain had the smallest market size at USD 173 million.
According to estimates, Japan’s market size for Herpes Simplex was around USD 349 million in 2023, with expectations of growth throughout the forecast period.
In 2023, the total diagnosed cases of Herpes Simplex in the 7MM were approximately 13,038 thousand. These cases are projected to rise over the study period from 2020 to 2034.
According to DelveInsight’s estimates, the United States accounted for approximately 38% of the total diagnosed prevalent cases of Herpes Simplex in the 7MM in 2023.
In 2023, gender-specific cases of Herpes Simplex in the EU4 and the UK were roughly 45% male and 55% female. These cases are expected to decline over time.
In 2023, Germany had the highest number of prevalent Herpes Simplex cases among the EU4 and the UK, followed by the UK, which recorded approximately 1,511 thousand cases.
In 2023, recurrent herpes simplex cases in Japan showed that HSV-2 accounted for more than 67%, while HSV-1 made up 33%.
Key Herpes Simplex Companies: Labo’Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others
Key Herpes Simplex Therapies: 2LHERP®, Pritelivir, GSK3943104, mRNA-1608, AMENALIEF (amenamevir), SITAVIG (acyclovir), famciclovir, ASP2151, BTL TML HSV, and others
The Herpes Simplex market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Herpes Simplex pipeline products will significantly revolutionize the Herpes Simplex market dynamics.
Herpes Simplex Overview
Herpes Simplex is a viral infection caused by the herpes simplex virus (HSV). It comes in two forms: HSV-1, which primarily causes oral herpes (cold sores), and HSV-2, which typically causes genital herpes. Both types can cause sores or blisters at the infection site and are transmitted through direct contact with the infected areas or bodily fluids. While there is no cure for herpes, antiviral treatments can help manage symptoms and reduce the risk of transmission. The virus can remain dormant in the body and reactivate periodically, causing recurrent outbreaks.
Get a Free sample for the Herpes Simplex Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/herpes-simplex-market
Herpes Simplex Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Herpes Simplex Epidemiology Segmentation:
The Herpes Simplex market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Seroprevalence of HSV in the 7MM
Total Symptomatic Cases of HSV in the 7MM
Total Diagnosed Cases of HSV in the 7MM
Gender-specific Diagnosed Cases of HSV in the 7MM
Total Recurrent Cases of HSV in the 7MM
Download the report to understand which factors are driving Herpes Simplex epidemiology trends @ Herpes Simplex Epidemiology Forecast
Herpes Simplex Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Herpes Simplex market or expected to get launched during the study period. The analysis covers Herpes Simplex market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Herpes Simplex Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Herpes Simplex Therapies and Key Companies
2LHERP®: Labo’Life
Pritelivir: AiCuris Anti-infective Cures AG
GSK3943104: GlaxoSmithKline
mRNA-1608: ModernaTX, Inc.
AMENALIEF (amenamevir): Maruho Co., Ltd.
SITAVIG (acyclovir): Bioalliance Pharma/Vectans Pharma
famciclovir: Novartis
ASP2151: Maruho Co., Ltd.
BTL TML HSV: Beech Tree Labs, Inc.
Discover more about therapies set to grab major Herpes Simplex market share @ Herpes Simplex Treatment Landscape
Herpes Simplex Market Strengths
The increase in healthcare expenditure in developing countries has increased access to healthcare services, including HSV treatment. This has increased the access to healthcare and surged the demand for herpes simplex virus treatment.
The chronic and recurrent nature of HSV infections creates a sustained need for ongoing care and treatment options in the market.
Herpes Simplex Market Opportunities
Collaboration between research institutes and healthcare sectors will immensely boost the market and its potential to make better curative therapies than existing palliative care.
Raising public awareness for herpes simplex infections can result in an earlier diagnosis and initiation of therapy ultimately boosting the financial state.
Scope of the Herpes Simplex Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Herpes Simplex Therapeutic Assessment: Herpes Simplex current marketed and Herpes Simplex emerging therapies
Herpes Simplex Market Dynamics: Herpes Simplex market drivers and Herpes Simplex market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Herpes Simplex Unmet Needs, KOL’s views, Analyst’s views, Herpes Simplex Market Access and Reimbursement
To know more about Herpes Simplex companies working in the treatment market, visit @ Herpes Simplex Clinical Trials and Therapeutic Assessment
Table of Contents
1. Herpes Simplex Market Report Introduction
2. Executive Summary for Herpes Simplex
3. SWOT analysis of Herpes Simplex
4. Herpes Simplex Patient Share (%) Overview at a Glance
5. Herpes Simplex Market Overview at a Glance
6. Herpes Simplex Disease Background and Overview
7. Herpes Simplex Epidemiology and Patient Population
8. Country-Specific Patient Population of Herpes Simplex
9. Herpes Simplex Current Treatment and Medical Practices
10. Herpes Simplex Unmet Needs
11. Herpes Simplex Emerging Therapies
12. Herpes Simplex Market Outlook
13. Country-Wise Herpes Simplex Market Analysis (2020–2034)
14. Herpes Simplex Market Access and Reimbursement of Therapies
15. Herpes Simplex Market Drivers
16. Herpes Simplex Market Barriers
17. Herpes Simplex Appendix
18. Herpes Simplex Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
